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Pancreatic carcinoma is a major cause of human cancer death. In
Japan, it is currently the fifth leading cause of cancer-related
mortality (Ministry of Health and Welfare, 1992). Pancreatic
carcinoma is difficult to diagnose, and a definitive curative
resection is possible in only approximately 10% of all patients
(Japanese Cancer Society, 1995). Therefore, if pancreatic carci-
nomas can be detected at an early stage, then the surgical results
should improve.
In recent years, an extremely sensitive polymerase chain reac-
tion (PCR) technique has been developed for the diagnosis of
various cancers (Harker et al, 1995; Mori et al, 1995; Eltahir et al,
1998). In pancreatic carcinoma, one of the most useful molecular
markers of this genetic method is K-ras oncogene (Motojima et al,
1991; Tada et al, 1991). Many researchers have reported that
approximately 90% of all pancreatic carcinomas contained a K-ras
oncogene activated by a mutation at codon 12 (Smith et al, 1988;
Almoguera et al, 1998; Bos, 1998). This particular genetic alter-
ation thus showed the K-ras oncogene to be a sensitive marker for
the presence of pancreatic carcinoma, and the K-ras mutation is
also easily detectable.
Circulating tumour cells have been reported to be detected in
the peripheral blood using the PCR technique (Tada et al, 1993;
Nomoto et al, 1996). In neuroblastoma, Mattano et al (1992)
described a highly sensitive detection assay for circulating neuro-
blasts in the peripheral blood using reverse transcription PCR (RT-
PCR), with the tissue-specific gene as a tumour marker. We thus
consider the pancreas-specific gene as a tumour marker to be
useful in diagnosing pancreatic carcinoma. In the present study,
we focused our attention on the chymotrypsinogen gene, which is
a pancreas-specific gene.
PATIENTS AND METHODS
Patients
The subjects in this study comprised ten patients with pancreatic
carcinoma (six male, four female; median age 61 years, range
48–77 years), two with acute pancreatitis (two male; 49 and 58
years) and three with chronic pancreatitis (two male, one female;
38, 47 and 68 years), who were all treated at our clinic. Ten healthy
volunteers were also included as controls (six male, four female;
median age 42 years, range 30–49 years).
RNA extraction
We collected the peripheral blood before operation in seven
patients with pancreatic carcinoma, while the other patient blood
samples were collected at the time of diagnosis. The peripheral
blood (10 ml) samples from the subjects were taken in the pres-
ence of potassium ethylenediaminetetraacetic acid (EDTA) and
then were promptly transported to the laboratory at 4°C for imme-
diate processing. In preparing and handling the RNA, we took
great care to avoid any degradation by contamination with
RNAases. The total cellular RNA was extracted from peripheral
blood using Trizol (Life Technologies, Inc., Grand Island, NY,
USA). The integrity of the RNA was checked electrophoretically
and quantified spectrophotometrically.
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First-strand cDNA was synthesized using SuperScript II reverse
transcriptase (Gibco-BRL Life Technologies, Inc., Gaithersburg,
MD, USA) and random hexanucleotide primers (Pharmacia Inc.,
Uppsala, Sweden). Four milligrams of total RNA were incubated
with 100 ng of random hexanucleotide primers in 11 ml of solution
for 5 min at 65°C. After chilling on ice, 4 ml of fivefold synthesis
buffer (250 mM Tris–HCl, pH 8.3, 375 mM potassium chloride, 15
mM magnesium chloride), 2 ml of 100 mM dithiothreitol, 1 ml of
dNTP (2.5 mM concentrations each of dATP, dCTP, dGTP and
dTTP), 1 ml of RNAase inhibitor (40 units ml–1; Toyobo, Tokyo,
Japan) and 1 ml of SuperScript II reverse transcriptase (200 units ml–1)
were added. The reaction mixture was then incubated for 1 h at 37°C
and the reaction was terminated by heating at 85°C for 10 min and
stored at –20°C until use. To standardize the samples and confirm the
presence of a cDNA template in each sample, a housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was also co-
amplified. Chymotrypsinogen gene-specific oligonucleotide primers
synthesized for the nested RT-PCR analysis, the sequences of the four
primers used were: outer sense, 5¢-CTCATCAGCGAGGACTGG-3¢;
outer anti-sense, 5¢-CAGGGCTGCCTGCTGCAG-3¢; inner sense,
5¢-CCCACTGCGGGGTCAGGA-3¢; inner antisense, 5¢-
GGGGTCTTGTTGGCGTTGTA-3¢.
The first-round PCR was carried out in a reaction mixture (25 ml)
containing 10 mM Tris (pH 8.3), 50 mM potassium chloride, 2.5 mM
magnesium chloride, 200 mM dNTP, 1.0 unit of Taq polymerase
(Takara Shuzo Co. Ltd, Tokyo, Japan), 100 pmol primers A and B,
and 1 ml of template cDNA. The samples were amplified at 35 PCR
cycles in the first step for 30 s at 94°C, 30 s at 55°C and 30 s at
72°C, with a final extension step at 72°C for 5 min. One millilitre of
each reaction product was then transferred into second tubes
containing the identical reaction mixture except for the primers, C
and D. These second step PCR cycles were identical to the first step
PCR. Ten microlitres of the second-step PCR products were then
electrophoresed on 2% agarose gel, followed by ethidium bromide
staining. The fragment size amplified from the GAPDH total RNA
templates by RT-PCR was 180 base pair (bp), and the nested RT-
PCR fragment size from the chymotrypsinogen total RNA was
280 bp. ‘No RT’ controls for all RT-PCR reactions were run as
above except that water was substituted for reverse transcriptase.
RESULTS
Specificity and sensitivity of chymotrypsinogen
RT-PCR
To confirm the chymotrypsinogen gene expressed in a pancreas-
specific manner, we examined the expression of the
chymotrypsinogen gene in various types of human adult tissue,
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Table 1 Profile of the pancreatic cancer patients and the results of chymotrypsinogen RT-PCR
Patient Tumur size Confirmation of
no. Age/Sex (cm)a malignancy Stagec RT-PCR assayd
1 75/F 3.5 Operation I +
2 48/M 4.0 Biopsy IV +
3 50/M 3.0 Operation III +
4 77/F 4.0 Operation III –
5 69/M 4.0 Combined methodsb –+
6 52/F 3.0 Operation III –
7 71/F 4.0 Operation III –
8 47/M 5.0 Operation IV +
9 52/M 4.5 Operation I +
10 66/M 5.5 Combined methods – +
aTumour size at its greatest dimension. bIncluding clinical examination, radiologic imaging and follow-up. cAccording to the 1987 UICC TNM classification of
malignant tumours. –: Stage is unknown. d+: positive for chymotrypsinogen gene. –: negative for chymotrypsinogen gene.
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Figure 1 Specificity of the chymotrypsinogen RT-PCR assay.
Chymotrypsinogen and GAPDH total RNA expression in various types of
normal tissue was analysed by nested RT-PCR, and the results of 2%
agarose gel electrophoresis containing 0.5 mg ml–1 ethidium bromide are
shown. Lane M, size marker (f X174/Hae III digest); lanes 1–14, various
tissue specimens (bile duct, gall bladder, skin, fat, muscle, peripheral blood,
ureter, small intestine, urinary bladder, prostate, colon, stomach, papilla of
Vater, liver); lane 15, pancreas; lane N, negative control (no template RNA
included)
Figure 2 Sensitivity of the chymotrypsinogen RT-PCR assay. Detection
sensitivity was determined by performing serial dilutions of total RNA from
pancreatic tissue and preparing the mixture with total RNA from the
peripheral blood. Lane M, a size marker (f X174/Hae III digest)352 T Kuroki et al
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including the bile duct, gall bladder, skin, fat, muscle, peripheral
blood, ureter, small intestine, urinary bladder, prostate, colon,
stomach, papilla of Vater, liver and pancreas by RT-PCR. As
shown in Figure 1, RT-PCR for chymotrypsinogen revealed a band
of a 280 bp fragment specifically in the pancreas.
Sensitivity was determined by performing serial dilutions of total
RNA extracted from normal pancreatic tissue, and by preparing
mixtures with total RNA extracted from normal peripheral blood to
represent 10–2–10–7 mg RNA of normal pancreatic tissue in 1 mg
RNA of normal peripheral blood. The chymotrypsinogen gene was
detected at a concentration of 10–6 mg normal pancreatic tissue
RNA in 1 mg normal peripheral blood RNA (Figure 2).
Patient samples
The RT-PCR assay revealed the peripheral blood from the ten
healthy volunteers used as control subjects, to be negative for the
chymotrypsinogen gene (data not shown). This assay resulted in
seven positives from the peripheral blood specimens from the ten
patients with pancreatic cancer (Figure 3), while tumour tissue
specimens were found to be positive for this gene in all cancer
patients (data not shown). However, no chymotrypsinogen-
specific band was detected in the peripheral blood from two
patients with acute pancreatitis and three patients with chronic
pancreatitis (Figure 3).
The association between the chymotrypsinogen RT-PCR
analysis and the clinical data of pancreatic carcinoma patients is
summarized in Table 1. Among the ten patients analysed, a histo-
logical confirmation was obtained from surgical specimens in
seven patients and from biopsy specimens in one patient. In two
patients, the diagnosis of pancreatic carcinoma was made based on
the physical stigmata and the findings of a radiological examina-
tion. These two patients did not undergo an operation, because
widespread lymph node metastases were detected using a com-
puterized tomography scan. The histopathological examination
revealed adenocarcinoma in seven patients and mucinous cyst
adenocarcinoma in one patient (patient no. 6). Two patients were
classified to be at UICC stage I, one was at stage III, two were
stage IV in the positive cases according to the findings of the RT-
PCR assay. All three patients were also stage III in the cases
diagnosed as negative with the RT-PCR assay.
DISCUSSION
Chymotrypsinogen is an inactive precursor of chymotrypsin, and
this enzyme is synthesized and secreted by the pancreas (Tomita et
al, 1989). The human chymotrypsinogen gene was confirmed to be
localized on chromosome 16q23 by fluorescence in situ hybridiza-
tion and G-band analysis (Hou et al, 1993). In our experiments, the
chymotrypsinogen gene was detected specifically in the pancreatic
tissue among the 15 normal tissue specimens including the periph-
eral blood. These results indicate that when circulating pancreatic
cancer cells are found in the peripheral blood, a diagnosis of
pancreatic carcinoma can be made. We hypothesized that an
extremely sensitive assay had the ability to detect a small number
of circulating cancer cells in the peripheral blood. In fact, Tada et
al (1993) reported circulating pancreatic cancer cells in the periph-
eral blood in two of six patients using the PCR technique to
any detect ras gene mutations. In the present study, detection
sensitivity studies using a serial dilution test revealed that a
chymotrypsinogen RT-PCR assay is sufficiently sensitive to detect
one pancreatic cell in 106 peripheral blood cells, provided that the
yield of total RNA from a pancreatic cell is equal to that from a
peripheral blood cell. This sensitivity is more sensitive than that
reported in the detection of micrometastases by either a cyto-
keratin 19 (Noguchi et al, 1996) or CEA RT-PCR (Nakanishi et al,
1997) assay using the RT-PCR technique.
The present study demonstrated that the chymotrypsinogen
gene could be detected in the peripheral blood based on the RT-
PCR findings in seven of the ten patients with pancreatic carci-
noma, but not in the ten healthy volunteers, two patients with acute
pancreatitis or the three patients with chronic pancreatitis. We
therefore considered the chymotrypsinogen gene in the peripheral
blood to be a specific tumour marker of pancreatic carcinoma.
The presence of K-ras mutations in various clinical samples was
thus found to be useful especially in confirming the diagnosis of
pancreatic carcinoma. However, several reports also demonstrated
K-ras gene mutations to be found in hyperplasia associated with
chronic pancreatitis (Yanagisawa et al, 1993; Tada et al, 1996).
Furthermore, this mutation of the K-ras gene has also been
reported in various human carcinomas (Bos et al, 1987; Anwar et
al, 1993; Kuo et al, 1994). On the other hand, cytokeratin 19 has
been reported to be a specific and sensitive molecular marker for
the detection of micrometastasis in various cancers (Schoenfeld et
al, 1994; Noguchi et al, 1996). We do not consider this marker to
be a pancreatic carcinoma-specific marker, because cytokeratin 19
has been reported to be a specific epithelial cell marker (Datta et
al, 1994). We need to find the specific molecular marker of pancre-
atic carcinoma. The results presented in this study suggest that our
chymotrypsinogen RT-PCR method is useful for specifically
detecting the presence of pancreatic carcinoma cells among the
thousands of normal cells.
To confirm the diagnosis of pancreatic carcinoma, various
clinical samples were used, including needle biopsy specimens
(Shibata et al, 1990), pancreatic juice (Kondo et al, 1994),
duodenal fluid (Wilentz et al, 1998) and bile (Ajiki et al, 1995)
from a choledochal drainage tube. However, the collection of
sufficient samples for a molecular diagnosis is often difficult.
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Figure 3 Detection of chymotrypsinogen RNA from the peripheral blood of
patient samples. (A) Lanes 1–10 correspond to patients 1–10 (Table 1); lane
M, size marker (f X174/Hae III digest); Lane P, positive control (human
pancreas tissue RNA); lane N, negative control (no template RNA included).
(B) Lanes 1 and 2, acute pancreatitis; lanes 3–5, chronic pancreatitisDetection of the pancreas-specific gene 353
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However, the collection of peripheral blood is rapid, easy and safe.
We therefore studied the possibility of making a genetic diagnosis
of pancreatic carcinoma by using peripheral blood.
The establishment of an easy method that can detect pancreatic
carcinomas at an earlier stage, when they are still resectable, may
thus help to improve the patient outcome. In the present study, the
pancreatic carcinoma tumour size did not show any significant
difference regarding the positivity of the chymotrypsinogen RT-
PCR assay (positive average 4.2 cm versus negative average
3.7 cm). Two stage I cases were found to show a positive result
based on the RT-PCR assay findings. These results suggested that
this easy and sensitive assay may be a valuable diagnostic tool in
the clinical diagnosis of pancreatic carcinoma at an early stage
using peripheral blood specimens. However, the negative cases for
the RT-PCR assay were all stage III. The reason we could not
detect the positive results of this RT-PCR assay in three cases of
advanced pancreatic carcinoma remains unknown. We still need to
prospectively study this chymotrypsinogen RT-PCR assay using
peripheral blood specimens of patients with pancreatic carcinoma.
We believe that the diagnostic role for this assay must be further
verified through the analysis of more patients and for longer
periods.
In conclusion, we demonstrated the chymotrypsinogen RT-PCR
assay to be a sensitive, simple and specific diagnostic method for
identifying pancreatic carcinoma at an early stage. This diagnostic
method using genetic techniques may potentially become a routine
diagnostic laboratory procedure and may thus contribute to an
improved outcome of patients with pancreatic carcinoma.
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